The safety and performance pathway and de novo clearance process are combining to reform the US Food and Drug Administration’s approach to device approvals, agency officials said on 14 September at RAPS Convergence 2020, hosted by the Regulatory Affairs Professionals Society.
FDA Gives Insight On Changing Approval Landscape
Device center officials at the US agency focused on new approval pathways at RAPS Convergence 2020.
More from Regulation
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
• By
About 200 staff in the FDA’s Center for Devices and Radiological Health were among the 3,500 FDA employees let go in today’s staff reductions. The cuts, which one employee described as a “Manhattan Project” to the center, are already having a major effect on staff morale.
AdvaMed’s top priorities for the 119th Congress include modernizing US Medicare services and expanding patients’ access to the latest medical technologies.
• By
Cybersecurity, sustainability and regulatory intelligence all need factoring into risk management today as AI and data availability change the goalposts. Eight experts tell Medtech Insight how compliance efforts must adapt.